Voxilaprevir is a pan-genotypic hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease inhibitor. It inhibits replication of wild-type HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a (EC50s = 1.9-6.6 nM in replicon assays). Voxilaprevir also inhibits replication of mutant HCV genotypes containing NS3 resistance-associated substitutions (EC50s = 3.1, 2.7, and 4 nM for HCV genotypes 1a Q80K, 1a R155K, and 1b D168E, respectively). Formulations containing Voxilaprevir have been used in the treatment of chronic HCV infection.

 

Brand: BCM

 

Target: Hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease

 

pKa: 4.46±0.40(Predicted)

 

Solubility: Soluble in DMSO. Insolublei n Water.

 

InChi Key: MZBLZLWXUBZHSL-FZNJKFJKSA-N

 

Attribute
[Chem Name]	(33R,34S,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide
[Synonym]	Voxilaprevir; GS-9857; GS 9857; GS9857; Vosevi
[CAS No.]	1535212-07-7
[MDL No.]	MFCD32174311
[Formula]	C40H52F4N6O9S
[Molecular]	868.93
[Form]	White solid

Goods Tag